Talaris Therapeutics Key Executives
This section highlights Talaris Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Talaris Therapeutics
(Showing 0 of )
Talaris Therapeutics Earnings
This section highlights Talaris Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for Talaris Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|
| Revenue | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $- | $- |
| Gross Profit | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $57.01M | $34.24M | $15.28M | $13.37M |
| General and Administrative Expenses | $19.47M | $13.26M | $7.41M | $5.01M |
| Selling and Marketing Expenses | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $19.47M | $13.26M | $7.41M | $5.01M |
| Other Expenses | $- | $- | $- | $- |
| Operating Expenses | $76.48M | $47.51M | $22.68M | $18.38M |
| Cost and Expenses | $76.48M | $47.51M | $22.68M | $18.38M |
| Interest Income | $900 | $- | $400 | $200 |
| Interest Expense | $2.58M | $- | $- | $- |
| Depreciation and Amortization | $2.16M | $623.00K | $447.00K | $379.00K |
| EBITDA | $-74.31M | $-46.88M | $-22.24M | $-18.00M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-76.48M | $-47.51M | $-22.68M | $-18.38M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $2.58M | $-326.00K | $-23.00K | $223.00K |
| Income Before Tax | $-73.89M | $-47.83M | $-22.71M | $-18.16M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $-5.17M | $326.00K | $23.00K | $-223.00K |
| Net Income | $-68.73M | $-48.16M | $-22.73M | $-17.93M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-16.66 | $-16.53 | $-34.00 | $-28.09 |
| EPS Diluted | $-16.66 | $-16.53 | $-34.00 | $-28.09 |
| Weighted Average Shares Outstanding | 4.12M | 2.91M | 668.51K | 638.33K |
| Weighted Average Shares Outstanding Diluted | 4.12M | 2.91M | 668.51K | 638.33K |
| SEC Filing | Source | Source | Source | Source |
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $267.00K | $4.09M | $13.41M | $14.64M | $14.98M | $13.19M | $14.20M | $10.59M | $9.18M | $7.57M | $6.47M | $4.38M | $3.96M | $3.40M | $3.54M |
| General and Administrative Expenses | $9.11M | $6.03M | $6.18M | $5.18M | $4.84M | $5.23M | $4.22M | $3.80M | $3.87M | $3.49M | $2.54M | $2.45M | $2.18M | $1.33M | $1.44M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $9.11M | $6.03M | $6.18M | $5.18M | $4.84M | $5.23M | $4.22M | $3.80M | $3.87M | $3.49M | $2.54M | $2.45M | $2.18M | $1.33M | $1.44M |
| Other Expenses | $89.00K | $6.39M | $4.48M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $9.47M | $10.11M | $19.60M | $19.82M | $19.82M | $18.41M | $18.41M | $14.39M | $13.06M | $11.06M | $9.01M | $6.83M | $6.14M | $4.74M | $4.97M |
| Cost and Expenses | $9.47M | $10.11M | $19.60M | $19.82M | $19.82M | $18.41M | $18.41M | $14.39M | $13.06M | $11.06M | $9.01M | $6.83M | $6.14M | $4.74M | $4.97M |
| Interest Income | $- | $1.76M | $- | $300 | $200 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $1.92M | $1.76M | $- | $1.77M | $812.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $-39.59K | $261.00K | $9.60M | $553.00K | $570.00K | $551.00K | $488.00K | $188.00K | $167.00K | $133.00K | $135.00K | $125.00K | $129.00K | $101.00K | $92.00K |
| EBITDA | $-8.93M | $-16.50M | $-14.48M | $1.74M | $-19.25M | $-17.86M | $-17.93M | $-14.20M | $-12.89M | $-10.92M | $-8.87M | $-6.71M | $-6.01M | $-4.64M | $-4.88M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-8.93M | $-16.50M | $-24.08M | $-19.82M | $-19.82M | $-18.41M | $-18.41M | $-14.39M | $-13.06M | $-11.06M | $-9.01M | $-6.83M | $-6.14M | $-4.74M | $-4.97M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $1.92M | $1.76M | $1.58M | $1.30M | $812.00K | $319.00K | $155.00K | $147.00K | $116.00K | $-295.00K | $-294.00K | $56.00K | $-279.00K | $74.00K | $126.00K |
| Income Before Tax | $-7.01M | $-14.74M | $-22.50M | $-18.53M | $-19.01M | $-18.10M | $-18.26M | $-14.24M | $-12.94M | $-11.35M | $-9.30M | $-6.78M | $-6.42M | $-4.66M | $-4.85M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $4.62M | $-1.58M | $-3.54M | $-812.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Income | $-7.01M | $-14.74M | $-20.92M | $-14.99M | $-18.20M | $-18.10M | $-18.26M | $-14.24M | $-12.94M | $-11.35M | $-9.30M | $-6.78M | $-6.42M | $-4.66M | $-4.85M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-1.64 | $-3.49 | $-5.00 | $-3.61 | $-4.40 | $-0.44 | $-0.45 | $-0.35 | $-0.32 | $-0.41 | $-0.23 | $-0.32 | $-0.30 | $-0.22 | $-0.23 |
| EPS Diluted | $-1.64 | $-3.49 | $-5.00 | $-3.61 | $-4.40 | $-0.44 | $-0.45 | $-0.35 | $-0.32 | $-0.41 | $-0.23 | $-0.32 | $-0.30 | $-0.22 | $-0.23 |
| Weighted Average Shares Outstanding | 4.27M | 4.22M | 4.18M | 4.15M | 4.14M | 41.09M | 40.98M | 40.93M | 40.67M | 27.37M | 41.24M | 21.19M | 21.19M | 21.19M | 21.19M |
| Weighted Average Shares Outstanding Diluted | 4.27M | 4.22M | 4.18M | 4.15M | 4.14M | 41.09M | 40.98M | 40.93M | 40.67M | 27.37M | 41.24M | 21.19M | 21.19M | 21.19M | 21.19M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|
| Cash and Cash Equivalents | $13.67M | $18.61M | $17.59M | $38.98M |
| Short Term Investments | $167.61M | $225.36M | $131.90M | $- |
| Cash and Short Term Investments | $181.28M | $243.97M | $149.49M | $38.98M |
| Net Receivables | $- | $- | $374.00K | $- |
| Inventory | $- | $- | $813.00K | $- |
| Other Current Assets | $4.33M | $2.54M | $76.00K | $39.00K |
| Total Current Assets | $185.61M | $246.51M | $150.75M | $40.79M |
| Property Plant Equipment Net | $7.99M | $4.80M | $2.01M | $1.13M |
| Goodwill | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- |
| Other Non-Current Assets | $111.00K | $104.00K | $14.00K | $20.00K |
| Total Non-Current Assets | $8.10M | $4.91M | $2.03M | $1.15M |
| Other Assets | $- | $- | $- | $1.00K |
| Total Assets | $193.72M | $251.42M | $152.78M | $41.94M |
| Account Payables | $3.89M | $2.56M | $767.00K | $667.00K |
| Short Term Debt | $910.00K | $- | $- | $- |
| Tax Payables | $- | $- | $156.00K | $32.00K |
| Deferred Revenue | $- | $- | $- | $- |
| Other Current Liabilities | $6.67M | $5.43M | $2.48M | $1.59M |
| Total Current Liabilities | $11.46M | $7.99M | $3.40M | $2.29M |
| Long Term Debt | $1.97M | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- |
| Other Non-Current Liabilities | $224.00K | $626.00K | $1.37M | $56.75M |
| Total Non-Current Liabilities | $2.20M | $626.00K | $1.37M | $56.75M |
| Other Liabilities | $- | $- | $- | $- |
| Total Liabilities | $13.66M | $8.61M | $4.77M | $59.04M |
| Preferred Stock | $- | $251.42M | $- | $- |
| Common Stock | $4.00K | $4.00K | $3.00K | $1.00K |
| Retained Earnings | $-164.74M | $-90.85M | $-43.01M | $-20.31M |
| Accumulated Other Comprehensive Income Loss | $-721.00K | $-78.00K | $-13.00K | $- |
| Other Total Stockholders Equity | $345.51M | $333.73M | $191.03M | $3.20M |
| Total Stockholders Equity | $180.06M | $242.81M | $148.00M | $-17.10M |
| Total Equity | $180.06M | $242.81M | $148.00M | $-17.10M |
| Total Liabilities and Stockholders Equity | $193.72M | $251.42M | $152.78M | $41.94M |
| Minority Interest | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $193.72M | $251.42M | $152.78M | $41.94M |
| Total Investments | $167.61M | $225.36M | $131.90M | $- |
| Total Debt | $2.88M | $- | $- | $- |
| Net Debt | $-10.79M | $-18.61M | $-17.59M | $-38.98M |
Balance Sheet Charts
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $67.08M | $18.35M | $24.22M | $13.67M | $18.47M | $25.52M | $22.79M | $18.61M | $27.31M | $36.30M | $9.89M | $17.59M |
| Short Term Investments | $79.94M | $133.90M | $141.59M | $167.61M | $175.40M | $181.59M | $202.74M | $225.36M | $227.42M | $229.92M | $130.21M | $131.90M |
| Cash and Short Term Investments | $147.02M | $152.25M | $165.81M | $181.28M | $193.87M | $207.11M | $225.53M | $243.97M | $254.73M | $266.22M | $140.10M | $149.49M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $477.00K | $374.00K |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.16M | $813.00K |
| Other Current Assets | $4.02M | $3.96M | $3.05M | $4.33M | $4.26M | $4.92M | $2.89M | $2.54M | $3.49M | $4.25M | $2.70M | $76.00K |
| Total Current Assets | $151.05M | $156.21M | $168.86M | $185.61M | $198.13M | $212.04M | $228.42M | $246.51M | $258.23M | $270.47M | $142.80M | $150.75M |
| Property Plant Equipment Net | $- | $1.05M | $3.64M | $7.99M | $8.31M | $8.77M | $8.72M | $4.80M | $2.99M | $2.25M | $2.08M | $2.01M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $14.00K | $1.86M | $111.00K | $111.00K | $111.00K | $111.00K | $111.00K | $104.00K | $104.00K | $89.00K | $14.00K | $14.00K |
| Total Non-Current Assets | $14.00K | $2.91M | $3.75M | $8.10M | $8.42M | $8.88M | $8.83M | $4.91M | $3.10M | $2.34M | $2.10M | $2.03M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $151.06M | $159.12M | $172.61M | $193.72M | $206.54M | $220.92M | $237.25M | $251.42M | $261.32M | $272.81M | $144.90M | $152.78M |
| Account Payables | $136.00K | $2.93M | $3.38M | $3.89M | $2.13M | $2.08M | $3.48M | $2.56M | $1.18M | $1.26M | $769.00K | $767.00K |
| Short Term Debt | $634.00K | $601.00K | $751.00K | $910.00K | $905.00K | $835.00K | $740.00K | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $48.00K | $156.00K |
| Deferred Revenue | $- | $6.35M | $- | $- | $- | $- | $3.10M | $- | $- | $- | $- | $- |
| Other Current Liabilities | $7.33M | $6.60M | $6.04M | $6.67M | $6.13M | $4.42M | $3.84M | $5.43M | $3.80M | $3.40M | $2.76M | $2.48M |
| Total Current Liabilities | $8.11M | $10.13M | $10.18M | $11.46M | $9.17M | $7.33M | $8.06M | $7.99M | $4.98M | $4.66M | $3.58M | $3.40M |
| Long Term Debt | $- | $425.00K | $521.00K | $1.97M | $2.20M | $2.43M | $2.66M | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $82.00K | $130.00K | $176.00K | $224.00K | $310.00K | $413.00K | $492.00K | $626.00K | $694.00K | $800.00K | $187.78M | $1.37M |
| Total Non-Current Liabilities | $82.00K | $555.00K | $697.00K | $2.20M | $2.51M | $2.84M | $3.15M | $626.00K | $694.00K | $800.00K | $187.78M | $1.37M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $8.19M | $10.69M | $10.88M | $13.66M | $11.68M | $10.17M | $11.22M | $8.61M | $5.68M | $5.46M | $191.37M | $4.77M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $- | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $1.00K | $3.00K |
| Retained Earnings | $-208.99M | $-201.98M | $-187.24M | $-164.74M | $-146.21M | $-127.20M | $-109.11M | $-90.85M | $-76.61M | $-63.66M | $-52.31M | $-43.01M |
| Accumulated Other Comprehensive Income Loss | $-115.00K | $-214.00K | $-299.00K | $-721.00K | $-1.22M | $-1.14M | $-926.00K | $-78.00K | $29.00K | $34.00K | $9.00K | $-13.00K |
| Other Total Stockholders Equity | $351.98M | $350.62M | $349.26M | $344.79M | $342.30M | $339.08M | $336.06M | $333.65M | $332.22M | $330.98M | $-9.00K | $191.03M |
| Total Stockholders Equity | $142.87M | $148.43M | $161.73M | $180.06M | $194.87M | $210.74M | $226.03M | $242.81M | $255.65M | $267.35M | $-46.47M | $148.00M |
| Total Equity | $142.87M | $148.43M | $161.73M | $180.06M | $194.87M | $210.74M | $226.03M | $242.81M | $255.65M | $267.35M | $-46.47M | $148.00M |
| Total Liabilities and Stockholders Equity | $151.06M | $159.12M | $172.61M | $193.72M | $206.54M | $220.92M | $237.25M | $251.42M | $261.32M | $272.81M | $144.90M | $152.78M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $151.06M | $159.12M | $172.61M | $193.72M | $206.54M | $220.92M | $237.25M | $251.42M | $261.32M | $272.81M | $144.90M | $152.78M |
| Total Investments | $79.94M | $133.90M | $141.59M | $167.61M | $175.40M | $181.59M | $202.74M | $225.36M | $227.42M | $229.92M | $130.21M | $131.90M |
| Total Debt | $634.00K | $1.03M | $1.27M | $2.88M | $3.10M | $3.27M | $3.40M | $- | $- | $- | $- | $- |
| Net Debt | $-66.45M | $-17.32M | $-22.95M | $-10.79M | $-15.36M | $-22.25M | $-19.39M | $-18.61M | $-27.31M | $-36.30M | $-9.89M | $-17.59M |
Annual Cash Flow
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|
| Net Income | $-73.89M | $-47.83M | $-22.71M | $-18.16M |
| Depreciation and Amortization | $2.16M | $623.00K | $447.00K | $379.00K |
| Deferred Income Tax | $- | $394.00K | $95.00K | $-38.00K |
| Stock Based Compensation | $11.16M | $3.78M | $1.02M | $229.00K |
| Change in Working Capital | $1.10M | $2.31M | $1.61M | $-85.00K |
| Accounts Receivables | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- |
| Accounts Payables | $1.66M | $1.32M | $100.00K | $321.00K |
| Other Working Capital | $-567.00K | $992.00K | $1.51M | $-406.00K |
| Other Non Cash Items | $-1.38M | $735.00K | $317.00K | $10.00K |
| Net Cash Provided by Operating Activities | $-60.86M | $-39.99M | $-19.21M | $-17.66M |
| Investments in Property Plant and Equipment | $-3.04M | $-2.44M | $-1.29M | $-562.00K |
| Acquisitions Net | $-58.71K | $93.95K | $- | $- |
| Purchases of Investments | $-191.58M | $-275.88M | $-158.24M | $- |
| Sales Maturities of Investments | $250.29M | $181.93M | $26.22M | $- |
| Other Investing Activities | $58.71K | $-93.95K | $-1.00K | $- |
| Net Cash Used for Investing Activities | $55.67M | $-96.39M | $-133.30M | $-562.00K |
| Debt Repayment | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- |
| Other Financing Activities | $242.00K | $137.40M | $131.12M | $36.20M |
| Net Cash Used Provided by Financing Activities | $242 | $137.40K | $131.12M | $36.20M |
| Effect of Forex Changes on Cash | $- | $- | $- | $-1.00K |
| Net Change in Cash | $-4.94M | $1.02M | $-21.39M | $17.98M |
| Cash at End of Period | $13.67M | $18.61M | $17.59M | $38.98M |
| Cash at Beginning of Period | $18.61M | $17.59M | $38.98M | $21.00M |
| Operating Cash Flow | $-60.86M | $-39.99M | $-19.21M | $-17.66M |
| Capital Expenditure | $-3.04M | $-2.44M | $-1.29M | $-562.00K |
| Free Cash Flow | $-63.90M | $-42.42M | $-20.50M | $-18.22M |
Cash Flow Charts
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-7.01M | $-14.74M | $-22.50M | $-18.53M | $-19.01M | $-18.10M | $-18.26M | $-14.24M | $-12.94M | $-11.35M | $-9.30M | $-6.78M | $-6.42M | $-4.66M | $-4.85M |
| Depreciation and Amortization | $- | $261.00K | $639.00K | $553.00K | $570.00K | $551.00K | $488.00K | $188.00K | $167.00K | $133.00K | $135.00K | $125.00K | $129.00K | $101.00K | $92.00K |
| Deferred Income Tax | $- | $-15.28M | $- | $- | $- | $- | $- | $- | $- | $109.00K | $193.00K | $226.00K | $- | $- | $- |
| Stock Based Compensation | $- | $1.17M | $3.66M | $3.07M | $3.04M | $2.85M | $2.20M | $994.00K | $1.05M | $896.00K | $835.00K | $593.00K | $186.00K | $120.00K | $123.00K |
| Change in Working Capital | $- | $-831.00K | $-149.00K | $2.02M | $2.27M | $-2.49M | $-709.00K | $3.21M | $1.52M | $-1.14M | $-1.27M | $175.00K | $999.00K | $1.00M | $-561.00K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $-413.00K | $-414.00K | $1.88M | $-131.00K | $-839.00K | $755.00K | $1.11M | $-287.00K | $496.00K | $1.00K | $6.00K | $-109.00K | $65.00K | $138.00K |
| Other Working Capital | $- | $-418.00K | $414.00K | $146.00K | $2.40M | $-1.65M | $-1.46M | $2.10M | $1.80M | $-1.64M | $-1.27M | $169.00K | $1.11M | $936.00K | $-699.00K |
| Other Non Cash Items | $7.01M | $14.74M | $1.45M | $-992.00K | $-294.00K | $-95.00K | $3.00K | $16.00K | $76.00K | $484.00K | $553.00K | $236.00K | $277.00K | $-52.00K | $-49.00K |
| Net Cash Provided by Operating Activities | $-7.01M | $-14.68M | $-16.90M | $-13.87M | $-13.43M | $-17.28M | $-16.28M | $-9.83M | $-10.13M | $-10.98M | $-9.05M | $-5.65M | $-4.83M | $-3.49M | $-5.24M |
| Investments in Property Plant and Equipment | $- | $-221.00K | $-320.00K | $-269.00K | $-341.00K | $-1.09M | $-1.34M | $-1.19M | $-726.00K | $-335.00K | $-187.00K | $-249.00K | $-342.00K | $-346.00K | $-349.00K |
| Acquisitions Net | $- | $-9.14K | $-27.73K | $-9.28K | $-6.64K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $-49.36M | $-25.27M | $-50.99M | $-52.60M | $-48.00M | $-39.98M | $-65.09M | $-35.95M | $-140.55M | $-34.30M | $-107.11M | $-28.02M | $-4.00M | $-19.11M |
| Sales Maturities of Investments | $- | $58.50M | $53.00M | $60.27M | $59.25M | $69.02M | $61.75M | $67.00M | $38.37M | $40.75M | $35.81M | $3.00M | $15.31M | $7.91M | $- |
| Other Investing Activities | $- | $9.14K | $27.73K | $9.28K | $6.64K | $- | $- | $- | $- | $- | $- | $-1.00K | $- | $- | $- |
| Net Cash Used for Investing Activities | $- | $8.92M | $27.41M | $9.01M | $6.30M | $19.93M | $20.43M | $721.00K | $1.69M | $-100.13M | $1.33M | $-104.36M | $-13.05M | $3.57M | $-19.45M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $-5 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $137.00K | $46.00K | $60.00K | $73.00K | $79.00K | $30.00K | $412.00K | $-551.00K | $137.52M | $17.00K | $-524.00K | $131.62M | $24.00K | $- |
| Net Cash Used Provided by Financing Activities | $- | $137.00K | $46.00K | $60 | $73 | $79 | $30 | $412 | $-551 | $137.52K | $17 | $-524.00K | $131.62M | $24.00K | $- |
| Effect of Forex Changes on Cash | $- | $-9.12M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-7.01M | $-5.62M | $10.55M | $-4.80M | $-7.05M | $2.73M | $4.18M | $-8.70M | $-8.99M | $26.41M | $-7.70M | $-110.54M | $113.75M | $97.00K | $-24.70M |
| Cash at End of Period | $-7.01M | $18.60M | $24.22M | $13.67M | $18.47M | $25.52M | $22.79M | $18.61M | $27.31M | $36.30M | $9.89M | $17.59M | $128.13M | $14.38M | $14.28M |
| Cash at Beginning of Period | $- | $24.22M | $13.67M | $18.47M | $25.52M | $22.79M | $18.61M | $27.31M | $36.30M | $9.89M | $17.59M | $128.13M | $14.38M | $14.28M | $38.98M |
| Operating Cash Flow | $-7.01M | $-14.68M | $-16.90M | $-13.87M | $-13.43M | $-17.28M | $-16.28M | $-9.83M | $-10.13M | $-10.98M | $-9.05M | $-5.65M | $-4.83M | $-3.49M | $-5.24M |
| Capital Expenditure | $- | $-221.00K | $-320.00K | $-269.00K | $-341.00K | $-1.09M | $-1.34M | $-1.19M | $-726.00K | $-335.00K | $-187.00K | $-249.00K | $-342.00K | $-346.00K | $-349.00K |
| Free Cash Flow | $-7.01M | $-14.90M | $-17.22M | $-14.14M | $-13.77M | $-18.37M | $-17.62M | $-11.02M | $-10.86M | $-11.32M | $-9.23M | $-5.90M | $-5.17M | $-3.84M | $-5.59M |
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
$2.72
Stock Price
$116.44M
Market Cap
74
Employees
Louisville, KY
Location
Revenue (FY )
$-
0.0% YoY
Net Income (FY )
$-
-42.7% YoY
EPS (FY )
$
-0.8% YoY
Free Cash Flow (FY )
$-
-50.6% YoY
Profitability
Gross Margin
0.0%
Net Margin
0.0%
ROE
-24.4%
ROA
-23.7%
Valuation
P/E Ratio
-7.02
P/S Ratio
0.00
EV/EBITDA
-5.39
Market Cap
$116.44M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-
-52.2% YoY
Free Cash Flow
$-
-50.6% YoY
Balance Sheet Summary
Total Assets
$-
-23.0% YoY
Total Debt
$-
0.0% YoY
Shareholder Equity
$-
-47.6% YoY
Dividend Overview
$0.15
Latest Dividend
%
Dividend Yield
%
Payout Ratio
Recent Dividend History
| Date | Amount | Type |
|---|---|---|
| 2023-10-20 | $0.15 | October 20, 23 |
Talaris Therapeutics Dividends
Explore Talaris Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
-8584.78x
Talaris Therapeutics Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.1512 | $1.5118 | October 20, 2023 | October 16, 2023 | October 20, 2023 | October 19, 2023 |
Talaris Therapeutics News
Read the latest news about Talaris Therapeutics, including recent articles, headlines, and updates.
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovascular disease (ASCVD) and other diseases
Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio
Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris” or the “Company”) today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the “Merger”) with Tourmaline Bio, Inc. (“Tourmaline”) pursuant to the Agreement and Plan of Merger, dated June 22, 2023 (the “Merger Agreement”). The special dividend, which the Company estimates will be $1.5118 per share of Talaris common stock, will be payable in cash.
New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics
This acquisition expands Comprehensive Cell Solutions, a business unit of NYBCe, capabilities and geographic reach as a commercial-scale cell therapy clinical development and manufacturing organization This acquisition expands Comprehensive Cell Solutions, a business unit of NYBCe, capabilities and geographic reach as a commercial-scale cell therapy clinical development and manufacturing organization
TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Talaris Therapeutics, Inc. (NasdaqGM: TALS) with Tourmaline Bio, Inc. pursuant to which Talaris shareholders will end up owning approximately 21.3% of the combined company, each on a fully diluted basis. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether th.
3 Hot Penny Stocks to Watch Before Next Week
Navigating the world of penny stocks can often feel like a dance, full of rhythm, calculated movements, and unexpected twists. One of the popular styles in this domain is swing trading, a strategy where investors profit from the ‘swing' or fluctuations in stock prices over a short period.
„MIR M: Vanguard & Vagabond“ – neues MMORPG von Wemade startet weltweit
SEOUL, Südkorea--(BUSINESS WIRE)--Wemade hat am 31. Januar 2023 offiziell sein MMORPG „MIR M: Vanguard & Vagabond“ (MIR M) in mehr als 170 Ländern der Welt eingeführt. „MIR M“ ist ein MMORPG in den Fußstapfen von „The Legend of Mir 2“, dem geistigen Eigentum (IP) von Wemade, das bei Spielern rund um den Globus Aufmerksamkeit erregte und die Welle der K-Spiele anführte. MIR M maximiert die einzigartige strategische Performance des Originalspiels mit „Gitter-Schlachtfeldern“ (Grid Battlegrounds), die zusätzlichen Spaß am taktischen Spiel versprechen, und „Viertel-Ansichten“ (Quarter-Views), die dem Spieler helfen, die Zusammensetzung der Schlacht schnell zu erkennen. Außerdem bietet es das neue Wachstumssystem „Mandala“ mit einem hohen Grad an Freiheit, das es den Spielern ermöglicht, verschiedene Zustände zu aktivieren und die Charaktere beliebig anzupassen. In den Spielen „Eroberung des verborgenen Tals“ (Hidden Valley Capture) und „Belagerung der Burg Sabuk“ (Sabuk Castle Siege) können die Spieler um wirtschaftliche Belohnungen und Macht kämpfen. In MIR M wurden das Game-Token „DRONE“ und das Governance-Token „DOGMA“ ergänzt, um eine „spielübergreifende Wirtschaft“ (Inter-Game Economy) mit MIR4 zu schaffen. Darüber hinaus wird es künftig einen NFT (Non-Fungible Token)-Handelsdienst für Spielcharaktere und Gegenstände anbieten. Wemade plant zahlreiche Events, um den offiziellen Start von MIR M zu feiern. Unter anderem werden Party Dungeons und Dungeon Raids veranstaltet sowie verschiedene Summon-Tickets und andere Gegenstände durch tägliche Check-In-Events verschenkt. Sobald „DOGMA“ und „DRONE“ nach dem offiziellen Start über das „Featured IMO“ zum „Fusion-Depot“ hinzugefügt werden, können „Reflect“-Inhaber Token über Airdrop-Events erhalten. MIR M, das 12 Sprachen unterstützt, kann aus dem Google Play Store, dem Apple App Store und von der offiziellen Website heruntergeladen werden. Weitere Informationen über MIR M finden Sie auf der offiziellen Website. Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.
Novel Spectrometry Platforms Market, 2022-2035: Need for Automation, Reproducibility and Higher Sensitivity Drives Adoption - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Novel Spectrometry Platforms Market, 2022-2035: Distribution by Type of Spectrometers, Company Size, End User Industry, Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering. The report features an extensive study on the current market landscape and future potential of novel spectrometers over the next decade. Over time, spectroscopy has emerged as an important analytical tool for accurate and rapid analysis of compounds. It finds applications in research activities in food, biotechnology, pharmaceutical and environmental industry. Spectroscopic instruments provide information on electronic and optical properties, chemical composition and crystallinity of compounds. There are several types of spectrometers, such as mass spectrometer, atomic absorption spectrometer, nuclear magnetic resonance (NMR), Raman spectrometer, and X-Ray fluorescence (XRF), which can be used for various qualitative and quantitative analyses. Amongst various spectrometry platforms, mass spectrometry is the most popular technique owing to its high quantitative accuracy, which can be further combined with liquid chromatography (LC/MS) and gas chromatography (GC/MS) for better resolution. Having said that, there are several challenges associated with these conventional spectrometers, such as lack of automation, resulting in lesser reproducibility and sensitivity of the systems. Novel spectrometers, having demonstrated the potential to address a number of challenges associated with conventional spectrometers, have emerged as an appropriate solution. It is also worth highlighting that several advancements, such as miniaturization, portability to increase performance and throughput of the process, have been made in the instrumentation of novel spectrometers. Around 30 companies are actively engaged in the manufacturing of novel spectrometry platforms that can be used for various analytical applications, quality control, structural biology, forensic investigations, material testing, and agriculture analysis. Further, various advanced technologies, such as new laser based system, have been introduced in the spectrometers to detect particular combination of compounds. Additionally, the field has witnessed several innovations in the data process, evolution in guidelines for processing of the instruments that are compliant with the regulatory standards, mainly based on data accuracy, speed of bioanalytical method and speed of the analysis. Moreover, in the last few years, stakeholders have undertaken several initiatives to augment their intellectual portfolio by filing 3000+ patents for latest technologies and products with advanced features. The growing popularity of novel spectrometry platforms is also evident from 60+ global events that have been organized in this field, since 2016. Given the rising interest of stakeholders towards technological advancements and growing adoption of novel spectrometers for various applications, we believe that the overall market for novel spectrometry platforms is anticipated to witness substantial growth in the coming years. Scope of the Report The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. In addition to other elements, the report includes: A detailed assessment of the current market landscape of novel spectrometry platforms, featuring information on the type of spectrometer, software platform, type of technology used, type of detector, weight of spectrometer and type of end user industry. In addition, the chapter includes analysis of novel spectrometry manufacturers, along with information on their year of establishment, company size, location of headquarters and leading players (in terms of number of products being offered). Elaborate profiles of the players offering novel spectrometry platforms (shortlisted on the basis of the year of experience of the company). Each profile features a brief overview of the company, financial information (if available), details on its product portfolio, and a section on recent developments and an informed future outlook. An analysis of over 700 peer-reviewed scientific articles related to novel spectrometry, published since 2018, based on several parameters, such as year of publication, type of article, emerging focus areas, most popular journals, most popular publishers and most popular copyright holders. A detailed analysis of global events attended by the participants, based on several relevant parameters, such as year of event, event platform, type of event, location of event, emerging focus areas, active organizers (in terms of number of events) and designation of participants. The chapter also highlights the geographical mapping of upcoming events. An insightful analysis of the patents filed / granted for novel spectrometry platforms, since 2018, taking into consideration various relevant parameters, such as type of patent, publication year, geographical location, CPC symbols, emerging focus areas, type of organization, leading players (in terms of number of patents granted / filed in the given time period) and patent characteristics. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis. An analysis of various developments / recent trends related to novel spectrometry, offering insights on partnerships and collaborations and recent initiatives being undertaken related to novel spectrometry platforms. A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall novel spectrometry platforms market. The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals: Nick Jones (Global Application and Development Director, LECO) Nicole Zhang (Product Manager, Shimadzu) Chris Henry (Senior Scientist, Waters) All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified. Key Questions Answered Who are the key players engaged in the development of novel spectrometry platforms? How has the intellectual property landscape in the novel spectrometry platforms evolved over the years? What are the key agenda items being discussed in various global events / conferences held novel spectrometry platforms? What is the focus area of the ongoing research activities related to novel spectrometry platforms? Which partnership models are most commonly adopted by stakeholders engaged in this industry? How is the current and future market opportunity, likely to be distributed across key market segments? Key Topics Covered: 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 4. NOVEL SPECTROMETRY PLATFORMS: MARKET LANDSCAPE 5. COMPANY PROFILES: NOVEL SPECTROMETRY PLATFORMS 6. PUBLICATION ANALYSIS 7. GLOBAL EVENT ANALYSIS 8. PATENT ANALYSIS 9. RECENT DEVELOPMENTS 10. SWOT ANALYSIS 11. MARKET FORECAST 12. CONCLUDING REMARKS 13. EXECUTIVE INSIGHTS 14. APPENDIX 1: TABULATED DATA 15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS Companies Mentioned Admesy Advion Interchim Scientific Agilent Technologies American Society for Biochemistry and Molecular Biology (ASBMB) American Society for Mass Spectrometry (ASMS) Avacta Avantes Bio-Rad Brigham Young University (BYU) Bruker Charles River Laboratories Coalesce Research Group Cobalt Light Systems (Acquired by Agilent Technologies) Cork Chamber Dalian Institute of Chemical Physics (DICP) Diagnostic anSERS Earle A. Chiles Research Institute Edinburgh Instruments Emerald Scientific Endress+Hauser European Reference Network for Critical Infrastructure Protection (ERNCIP) Evoke MicroMass Excellims Extrel (Acquired by Process Insights) Flash Photonics French Society of Mass Spectrometry (SFSM) Genedata George Mason University German Society for Mass Spectrometry (DGMS) HORIBA Innovative Photonic Solutions (IPS) Instrument Systems Intabio (Acquired by Sciex) International Mass Spectrometry Foundation (IMSF) International Scientific Advisory Committee (ISAC) International Society for Ion Mobility Spectrometry (ISIMS) IonSense (Acquired by Bruker) IONTOF USA Iowa State University JEOL Karlsruhe Institute of Technology (KIT) Kore Technology Kratos Analytical Kyungpook National University (KNU) Labroots League of advanced European Neutron Sources (LENS) LECO Mass Spectrometry Core (Maintained by Office of Research and Innovation) Massachusetts Institute of Technology (MIT) Megadalton Solutions Mestrelab Metrohm Newomics Nexus Conferences NJ Biopharmaceuticals Ocean Insight PerkinElmer Photonics Spectra Protein Metrics Providence Cancer Institute Purdue Research Foundation (PRF) Quest Diagnostics RESANET Royal Society of Chemistry (RSC) Scienta Omicron SCIEX Semiconductor Energy Laboratory (SEL) SepSolve Analytical SGS AXYS Shanghai Spectrum Instruments (SSI) (Acquired by PerkinElmer) Shimadzu Skyray Instrument SPECTRAL Industries Stanford University TALS Teledyne FLIR Teledyne Princeton Instruments Thermo Finnigan Thermo Fisher Scientific University of California University of North Carolina University of Queensland University of Tartu University of Texas Utrecht University Waters Wiley Analytical Science For more information about this report visit https://www.researchandmarkets.com/r/g6wryq
Talaris Therapeutics' stock falls 21% after reporting patient death in clinical trial
Shares of Talaris Therapeutics Inc. TALS, -1.63% tumbled 21.5% in premarket trading on Thursday after the company reported one of the participants in its Phase 3 study of living donor kidney transplant recipients died. The patient had been diagnosed with a moderate form of acute graft-vs-host disease.
Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa
BOSTON and LOUISVILLE, Ky., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the 2022 Cell & Gene Meeting on the Mesa being held October 11-13, 2022 in Carlsbad, California and livestreamed globally. In addition, members from the management team will also be in attendance.
Talaris Therapeutics to Present at William Blair's Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event
BOSTON and LOUISVILLE, Ky., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at William Blair's Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event on Wednesday, September 28, 2022 at 1:00 PM ET.
Talaris Therapeutics to Participate in Two Upcoming Investor Conferences
BOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that members of its senior management team will participate in the following investor conferences:
Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk
Shares of cell therapy concern Talaris Therapeutics crashed nearly 70% after GvHD outcomes in three Phase 3 trial kidney transplant patients were revealed at the end of June 2022. Even though its stock has essentially doubled off its update-induced low, it still trades at a discount to cash.
Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study
BOSTON and LOUISVILLE, Ky., June 01, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced it will host a conference call to discuss its presentations at the American Transplant Congress (ATC) and provide a data update from its ongoing Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients.
Talaris Therapeutics to Present at the Jefferies Healthcare Conference
BOSTON and LOUISVILLE, Ky., May 31, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 10:30 AM ET at the Marriott Marquis in New York, NY.
Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference
BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced today announced that Scott Requadt, Chief Executive Officer of Talaris, will be presenting virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022.
Talaris Therapeutics to Participate at Two Upcoming Investor Conferences
BOSTON and LOUISVILLE, Ky., March 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune disorders, today announced that members of its senior management team will participate at the following investor conferences:
Talaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
BOSTON and LOUISVILLE, Ky., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 8:40 AM ET.
Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
BOSTON and LOUISVILLE, Ky., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 PM ET.
Talaris Therapeutics to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
BOSTON and LOUISVILLE, Ky., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022.
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index
ATLANTA & NEW YORK--(BUSINESS WIRE)--Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of data, technology and market infrastructure, today announced the annual reconstitution of the ICE Biotechnology Index (ICEBIO), which is effective before the open of trading on Monday, December 20, 2021. The ICE Biotechnology Index tracks the performance of qualifying U.S. listed biotechnology companies classified within the Biotechnology Sub-Industry Group of the ICE Uniform Sector Classification schema, which is a multi-asset class industry classification taxonomy developed by ICE. The index includes companies that are engaged in the research and development of therapeutic treatments but are not focused on the commercialization and mass production of pharmaceutical drugs. The index also includes companies that are engaged in the production of tools or systems that enable biotechnology processes. “This annual reconstitution ensures that the index maintains its representation of the broader biotechnology industry,” said Aram Flores, Head of Index and Analytics at ICE. “By including companies meeting a minimum threshold of market capitalization and liquidity from multiple U.S. exchanges, the index provides a better gauge of the biotechnology industry and helps improve the investability for users benchmarking to the index.” The following companies will be added to and removed from the index in the December 2021 annual reconstitution: Ticker Name Action ABCL AbCellera Biologics, Inc. Addition ABCM Abcam PLC Sponsored ADR Addition ABOS Acumen Pharmaceuticals, Inc. Addition ABSI Absci Corporation Addition ACET Adicet Bio Inc Addition ACHL Achilles Therapeutics PLC Sponsored ADR Addition ACRS Aclaris Therapeutics, Inc. Addition ADMA ADMA Biologics, Inc. Addition AKUS Akouos, Inc. Addition AKYA Akoya Biosciences Inc Addition ALGS Aligos Therapeutics, Inc. Addition ALPN Alpine Immune Sciences, Inc. Addition ALVR AlloVir Inc Addition AMPE Ampio Pharmaceuticals, Inc. Addition ANVS Annovis Bio Inc Addition ATAI ATAI Life Sciences N.V. Addition ATHA Athira Pharma, Inc. Addition AUPH Aurinia Pharmaceuticals Inc. Addition AUTL Autolus Therapeutics Plc Sponsored ADR Addition AVIR Atea Pharmaceuticals, Inc. Addition AVTE Aerovate Therapeutics, Inc. Addition AVXL Anavex Life Sciences Corp. Addition BCAB BioAtla, Inc. Addition BCYC Bicycle Therapeutics Plc Sponsored ADR Addition BLU BELLUS Health Inc. Addition BMEA Biomea Fusion Inc Addition BNR Burning Rock Biotech Ltd. Sponsored ADR Class A Addition BOLT Bolt Biotherapeutics, Inc. Addition BTX Brooklyn ImmunoTherapeutics, Inc. Addition CADL Candel Therapeutics, Inc. Addition CCCC C4 Therapeutics, Inc. Addition CDAK Codiak BioSciences, Inc. Addition CGEM Cullinan Oncology, Inc. Addition CLSD Clearside Biomedical, Inc. Addition CMPS COMPASS Pathways Plc Sponsored ADR Addition CMRX Chimerix, Inc. Addition CNTA Centessa Pharmaceuticals PLC ADR Addition CNTB Connect Biopharma Holdings Ltd. Sponsored ADR Addition CRBU Caribou Biosciences, Inc. Addition CRIS Curis, Inc. Addition CTKB Cytek Biosciences, Inc. Addition CVAC CureVac N.V. Addition CYBN Cybin, Inc. Addition CYT Cyteir Therapeutics, Inc. Addition DAWN Day One Biopharmaceuticals, Inc. Addition DBTX Decibel Therapeutics, Inc. Addition DBVT DBV Technologies SA Sponsored ADR Addition DNAY Codex DNA, Inc. Addition DSGN Design Therapeutics, Inc. Addition DYN Dyne Therapeutics Inc Addition ERAS Erasca, Inc. Addition ETNB 89bio Inc Addition EVLO Evelo Biosciences, Inc. Addition EWTX Edgewise Therapeutics, Inc. Addition FDMT 4D Molecular Therapeutics, Inc. Addition GLUE Monte Rosa Therapeutics, Inc. Addition GRCL Gracell Biotechnologies Inc. Sponsored ADR Class A Addition GRPH Graphite Bio, Inc. Addition GRTS Gritstone bio, Inc. Addition GTH Genetron Holdings Ltd Sponsored ADR Addition HBIO Harvard Bioscience, Inc. Addition HOWL Werewolf Therapeutics, Inc. Addition HUMA Humacyte, Inc. Addition ICVX Icosavax, Inc. Addition IKNA Ikena Oncology, Inc. Addition IMGO Imago BioSciences, Inc. Addition IMMP Immutep Ltd Sponsored ADR Addition IMPL Impel NeuroPharma, Inc. Addition IMRX Immuneering Corp. Class A Addition INBX Inhibrx Inc Addition INFI Infinity Pharmaceuticals, Inc. Addition IPHA Innate Pharma SA Sponsored ADR Addition IPSC Century Therapeutics, Inc. Addition JANX Janux Therapeutics, Inc. Addition KMDA Kamada Ltd Addition KMPH KemPharm, Inc. Addition KNTE Kinnate Biopharma, Inc. Addition KRON Kronos Bio Inc Addition KYMR Kymera Therapeutics, Inc. Addition LABP Landos Biopharma, Inc. Addition LCTX Lineage Cell Therapeutics, Inc. Addition LPTX Leap Therapeutics, Inc. Addition LYEL Lyell Immunopharma, Inc. Addition MBIO Mustang Bio, Inc. Addition MIRM Mirum Pharmaceuticals, Inc. Addition MORF Morphic Holding, Inc. Addition MREO Mereo BioPharma Group plc Sponsored ADR Addition MRUS Merus N.V. Addition MRVI Maravai LifeSciences Holdings Inc Class A Addition MTEM Molecular Templates, Inc. Addition MTNB Matinas BioPharma Holdings, Inc. Addition MXCT MaxCyte, Inc. Addition NAUT Nautilus Biotechnolgy, Inc. Addition NRXP NRX Pharmaceuticals, Inc. Addition NUVB Nuvation Bio Inc Class A Addition NUVL Nuvalent, Inc. Class A Addition OBSV ObsEva SA Addition OCX Oncocyte Corporation Addition OLK Olink Holding AB Sponsored ADR Addition OLMA Olema Pharmaceuticals, Inc. Addition OMGA Omega Therapeutics, Inc. Addition OMIC Singular Genomics Systems, Inc. Addition ONCR Oncorus, Inc. Addition OYST Oyster Point Pharma Inc Addition PCVX Vaxcyte, Inc. Addition PHAT Phathom Pharmaceuticals, Inc. Addition PMVP PMV Pharmaceuticals, Inc. Addition PRAX Praxis Precision Medicines, Inc. Addition PRLD Prelude Therapeutics, Inc. Addition PRQR ProQR Therapeutics N.V. Addition RAIN Rain Therapeutics Inc Addition RANI Rani Therapeutics Holdings, Inc. Class A Addition RLYB Rallybio Corporation Addition ROIV Roivant Sciences Ltd. Addition RXDX Prometheus Biosciences, Inc Addition RXRX Recursion Pharmaceuticals, Inc Class A Addition SANA Sana Biotechnology, Inc. Addition SBTX Silverback Therapeutics, Inc. Addition SEER Seer, Inc. Class A Addition SESN Sesen Bio, Inc. Addition SLDB Solid Biosciences Inc. Addition SMMT Summit Therapeutics Inc Addition SNSE Sensei Biotherapeutics, Inc. Addition SQZ SQZ Biotechnologies Company Addition STTK Shattuck Labs, Inc. Addition STVN Stevanato Group SpA Addition SYNH Syneos Health, Inc. Class A Addition TALS Talaris Therapeutics, Inc. Addition TERN Terns Pharmaceuticals, Inc. Addition TIL Instil Bio, Inc. Addition TKNO Alpha Teknova, Inc. Addition TNYA Tenaya Therapeutics, Inc. Addition TSHA Taysha Gene Therapies, Inc. Addition VERV Verve Therapeutics, Inc. Addition VIRX Viracta Therapeutics, Inc. Addition VOR Vor Biopharma, Inc. Addition VRCA Verrica Pharmaceuticals Inc. Addition AMRS Amyris, Inc. Deletion APRE Aprea Therapeutics, Inc. Deletion ARDX Ardelyx, Inc. Deletion ASMB Assembly Biosciences, Inc. Deletion BCEL Atreca, Inc. Class A Deletion CALA Calithera Biosciences, Inc. Deletion CERS Cerus Corporation Deletion CNCE Concert Pharmaceuticals, Inc. Deletion EGRX Eagle Pharmaceuticals, Inc. Deletion ESPR Esperion Therapeutics, Inc. Deletion GH Guardant Health, Inc. Deletion INZY Inozyme Pharma, Inc. Deletion KALA Kala Pharmaceuticals, Inc. Deletion KLDO Kaleido Biosciences, Inc. Deletion MNOV MediciNova, Inc. Deletion MOR MorphoSys AG Sponsored ADR Deletion NCNA NuCana plc Sponsored ADR Deletion ODT Odonate Therapeutics, Inc. Deletion OMER Omeros Corporation Deletion SIGA SIGA Technologies Inc Deletion SUPN Supernus Pharmaceuticals, Inc. Deletion TLSA Tiziana Life Sciences Ltd. Deletion UBX Unity Biotechnology, Inc. Deletion VRNA Verona Pharma plc Sponsored ADR Deletion VYGR Voyager Therapeutics, Inc. Deletion XBIT XBiotech, Inc. Deletion ICE’s global family of indices serve as the performance benchmark for more than $1 trillion in assets managed by investors around the globe. For more information about ICE’s Indices, please visit: https://www.ice.com/market-data/indices. About Intercontinental Exchange Intercontinental Exchange, Inc. (NYSE: ICE) is a Fortune 500 company that designs, builds and operates digital networks to connect people to opportunity. We provide financial technology and data services across major asset classes that offer our customers access to mission-critical workflow tools that increase transparency and operational efficiencies. We operate exchanges, including the New York Stock Exchange, and clearing houses that help people invest, raise capital and manage risk across multiple asset classes. Our comprehensive fixed income data services and execution capabilities provide information, analytics and platforms that help our customers capitalize on opportunities and operate more efficiently. At ICE Mortgage Technology, we are transforming and digitizing the U.S. residential mortgage process, from consumer engagement through loan registration. Together, we transform, streamline and automate industries to connect our customers to opportunity. Trademarks of ICE and/or its affiliates include Intercontinental Exchange, ICE, ICE block design, NYSE and New York Stock Exchange. Information regarding additional trademarks and intellectual property rights of Intercontinental Exchange, Inc. and/or its affiliates is located here. Key Information Documents for certain products covered by the EU Packaged Retail and Insurance-based Investment Products Regulation can be accessed on the relevant exchange website under the heading “Key Information Documents (KIDS).” Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 -- Statements in this press release regarding ICE's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ICE's Securities and Exchange Commission (SEC) filings, including, but not limited to, the risk factors in ICE's Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on February 4, 2021. SOURCE: Intercontinental Exchange ICE-CORP
Talaris Therapeutics to Participate at Three Upcoming Virtual Investor Conferences
BOSTON and LOUISVILLE, Ky., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced that members of its senior management team will participate at the following investor conferences:
Talaris Therapeutics Announces Upcoming Presentations and Investor Conference Call During American Society of Nephrology Meeting
BOSTON and LOUISVILLE, Ky., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company, today announced upcoming data presentations at the American Society of Nephrology (ASN) Kidney Week 2021, taking place November 4-7, 2021.
Das MMORPG „MIR4“ von Wemade erhält im September das erste große Update
SEOUL, Südkorea--(BUSINESS WIRE)--Nach dem erfolgreichen weltweiten Release wird „MIR4“ das erste große Update erhalten. Es werden zusätzliche Inhalte enthüllt, darunter der erste globale Clan-Kampf, die Clan-Challenge und das Einsamkeitstraining. Heute (10. September) wurde ein weiterer Kerninhalt, „Schattental-Eroberung“ (Eroberung des Verborgenen Tals), veröffentlicht. Der Kampf um die Eroberung des Hidden Valley ist ein Kampf zwischen verschiedenen Clans um die Kontrolle über die Quelle der wichtigsten Ressource des Spiels, Darksteel. Er wird ab dem 15. September jeden Mittwoch um 22 Uhr (lokale Serverzeit) stattfinden. „Der Clan, der das Hidden Valley besetzt, gewinnt enorm an Macht und die Befugnis, den Handel mit Darksteel zu betreiben“, so Wemade. „Clans können die Minen monopolisieren, indem sie den Zugang zum Hidden Valley kontrollieren, oder sie können das geförderte Darksteel zum Nutzen des Clans besteuern. Darksteel kann in den Utility-Coin Draco eingeschmolzen und gegen den virtuellen Vermögenswert Wemix-Token eingetauscht werden. Damit wird eine Verbindung zwischen Ressourcen im Spiel und realen Vermögenswerten geschaffen. Daher wirken sich Clankämpfe letztendlich auf die echte Ökonomie aus und führen so zu intensiveren Clankämpfen.“ Aufgrund des rasanten Anstiegs der Spielerzahlen wurde eine neue Serverregion, SA (Südamerika), hinzugefügt, so dass Spieler aus Südamerika das Spiel in einer besseren Spielumgebung genießen können. Weitere Informationen finden Sie auf der offiziellen Website. „From my battle to our war! (Von meiner Schlacht zu unserem Krieg!)” MMORPG „MIR4“ Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.
Talaris Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
BOSTON and LOUISVILLE, Ky., June 14, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today reported financial results for the three-month period ended March 31, 2021, and provided an update on its business.
Talaris Therapeutics Announces Closing of Initial Public Offering
BOSTON and LOUISVILLE, Ky. , May 11, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced the closing of its initial public offering of 8,825,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds of the offering were approximately $150.0 million, before deducting underwriting discounts and commissions and other offering expenses. The shares began trading on the Nasdaq Global Market on May 7, 2021 under the symbol “TALS.” All shares in the offering were offered by Talaris Therapeutics. In addition, the underwriters have a 30-day option to purchase up to an additional 1,323,750 shares of common stock at the initial public offering price less underwriting discounts and commissions.
Talaris Therapeutics Announces Pricing of Initial Public Offering
BOSTON and LOUISVILLE, Ky., May 06, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today announced the pricing of its initial public offering of 8,825,000 shares of common stock at a price to the public of $17.00 per share. All shares are being offered by Talaris. The gross proceeds to Talaris from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $150.0 million. The shares are expected to begin trading on The Nasdaq Global Select Market under the ticker symbol “TALS” on May 7, 2021. The offering is expected to close on May 11, 2021, subject to the satisfaction of customary closing conditions. In addition, the underwriters have a 30-day option to purchase up to an additional 1,323,750 shares of common stock at the initial public offering price less underwriting discounts and commissions.
Ägypten fasziniert die Welt mit einem Pharaonenumzug in goldenen Wagen
Kairo--(BUSINESS WIRE)--Zweiundzwanzig Pharaonenmumien wurden am Samstagabend in einer bezaubernden königlichen Prozession vom Ägyptischen Museum am Tahrirplatz durch die Straßen von Kairo ins neue Nationalmuseum für Ägyptische Zivilisation (NMEC) in Fustat gefahren. Die Veranstaltung kennzeichnete die offizielle Eröffnung des NMEC. Vor dem Hintergrund aus Feuerwerk reisten die Mumien – 18 Könige und vier Königinnen – nach Alter sortiert auf eigens für diese Veranstaltung gebauten goldfarbenen Pharaonenwagen, die zur Schwingungsdämpfung mit einem Luftfedersystem ausgestattet waren und die Namen ihrer Passagiere auf Arabisch, Englisch und in Hieroglyphen trugen. Seqenenre Taa II., der etwa 1.600 v. Chr. das Obere Ägypten beherrschte, führte den Umzug an, während Ramses IX., der im 12. Jahrhundert v. Chr. herrschte, den Umzug abschloss. Gemäß strenger internationaler Standards für die Beförderung von Artefakten wurden die königlichen Überreste in modernste sterile Vitrinen gelegt, um eine einwandfreie Aufbewahrung zu gewährleisten. Begleitet wurde der Umzug von 60 Motorrädern, 150 Pferden und einem pharaonischen Musikensemble unter der Leitung des renommierten ägyptischen Dirigenten Nader Abbassi. Die Prozession wurde mit 21 Salutschüssen eröffnet, umfuhr den Obelisken am nahegelegenen Tahrirplatz und fuhr dann entlang des Nils zum NMEC, wo der ägyptische Präsident Abdel Fattah El-Sisi höchstpersönlich die Mumien in ihrer neuen Residenz in Fustat, dem Nationalmuseum für Ägyptische Zivilisation, begrüßte. An der 40-minütigen Parade nahmen 12 ägyptische Berühmtheiten teil und sie wurde von über 200 internationalen Fernsehsendern übertragen. Die kostbaren Artefakte werden im Laufe der nächsten zwei Wochen im Labor des NMEC für die Installation in der Halle der Königlichen Mumien in Nachahmung des Tals der Könige vorbereitet. Die Halle der Königlichen Mumien wird ihre Türen am 18. April, also zum Tag des Weltkulturerbes, für Besucher öffnen. Zur Eröffnung bietet das NMEC Eintrittskarten zur Zentralen Ausstellungshalle für alle Besucher zwischen dem 4. und 17. April zum halben Preis an. Außerdem erhalten Vertreter lokaler und internationaler Medien die Gelegenheit, die Artefakte im Inneren der Zentralen Ausstellungshalle am 4. und 5. April kostenlos zu fotografieren und zu filmen. Das NMEC gewährt einen Ausblick auf Ain Al-Sira in der historischen Stadtmitte von Fustat nahe der Festung Babylon und ist eines der weltweit größten und bedeutendsten Archäologiemuseen sowie das erste Museum, das die gesamte ägyptische Zivilisation umfasst. *Quelle: AETOSWire Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for TALS.